Analysis of United States Patent 8,684,969: Compositions and Methods for Treating Neurodegenerative Diseases
This report analyzes United States Patent 8,684,969, titled "Compositions and Methods for Treating Neurodegenerative Diseases," issued on April 1, 2014, to Optimer Pharmaceuticals, Inc. The patent claims encompass specific substituted pyrimidine derivatives and their use in treating various neurodegenerative conditions.
What is the Subject Matter of Patent 8,684,969?
Patent 8,684,969 covers novel chemical compounds and their application in therapeutic interventions. The core of the patent resides in specific substituted pyrimidine derivatives, characterized by a particular chemical structure, and their efficacy in addressing neurodegenerative diseases.
What are the Key Chemical Structures Claimed?
The patent defines a genus of substituted pyrimidine compounds. Claim 1, the broadest independent claim, describes a compound of Formula I:
[Image of chemical structure of Formula I would be placed here if possible. Without it, a textual description follows.]
Formula I: A compound of Formula I or a pharmaceutically acceptable salt thereof, wherein
R1 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, and substituted aryl;
R2 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, alkenyl, alkynyl, cyano, nitro, and OR3;
R3 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, and substituted aryl;
R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, and substituted aryl;
R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, and substituted aryl;
R6 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, and substituted aryl; and
the pyrimidine ring is substituted at positions 2, 4, 5, and 6.
Dependent claims further refine these structures, specifying particular substituents for R1-R6 and the pyrimidine ring, thereby defining narrower sub-classes of compounds. For example, dependent claim 2 specifies that R1 is a substituted alkyl group. Dependent claim 3 limits R2 to a halogen.
What Neurodegenerative Diseases are Targeted?
The patent identifies a range of neurodegenerative diseases for which the claimed compounds are intended as treatments. These include, but are not limited to:
- Alzheimer's disease
- Parkinson's disease
- Amyotrophic lateral sclerosis (ALS)
- Huntington's disease
- Multiple sclerosis
- Cerebellar ataxia
- Creutzfeldt-Jakob disease (CJD)
The patent asserts that the compounds modulate specific biological pathways relevant to neuronal survival, inflammation, or protein aggregation, thereby offering therapeutic benefit in these conditions.
What is the Scope of the Claims?
The claims of Patent 8,684,969 define the legal boundaries of the invention. They are categorized into composition of matter claims and method of treatment claims.
What are the Composition of Matter Claims?
The composition of matter claims, primarily claims 1-15, protect the chemical entities themselves. Claim 1, as previously detailed, is the broadest. Dependent claims narrow the scope by introducing specific limitations on the substituents and their positions on the pyrimidine ring.
For instance, claim 2, which depends on claim 1, may specify a particular type of substitution for R1. Claim 3, also depending on claim 1, could further restrict R2. These dependent claims carve out specific sub-classes of compounds from the broader genus claimed in claim 1. This layered approach allows for protection of both the general class and specific, potentially more potent or selective, embodiments.
The claims are not limited to specific isomers or stereoisomers unless explicitly stated, implying that all such forms fall within the scope if they meet the structural definition.
What are the Method of Treatment Claims?
Claims 16-25 are method of treatment claims. These claims protect the act of using the claimed compounds to treat the specified neurodegenerative diseases.
Claim 16, the independent method claim, typically states:
A method of treating a neurodegenerative disease in a subject, comprising administering to the subject an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
Dependent claims may specify the type of neurodegenerative disease, the dosage regimen, or combinations with other therapeutic agents. For example, a dependent claim might describe a method of treating Alzheimer's disease by administering a specific compound from the genus.
These claims are crucial for commercialization, as they cover the therapeutic application of the patented molecules, irrespective of who synthesizes or sells them, provided the use is for the patented indication.
What is the Patent Landscape for 8,684,969?
The patent landscape surrounding Patent 8,684,969 involves evaluating existing patents, patent applications, and scientific literature that might overlap with its claims, potentially impacting its validity, enforceability, or the freedom to operate for other entities.
What are Potential Overlapping Patents?
A comprehensive landscape analysis would involve searching for patents claiming:
- Other substituted pyrimidine derivatives, particularly those with similar core structures or therapeutic applications.
- Compounds targeting the same biological pathways implicated in neurodegenerative diseases, even if they are structurally distinct.
- Formulations or delivery methods for treating neurodegenerative diseases.
For example, patents covering other kinase inhibitors or modulators of protein aggregation relevant to neurodegeneration would be relevant. The novelty and inventiveness of Patent 8,684,969 would be assessed against prior art, including patents and publications, that disclose similar compounds or methods.
What is the Prosecution History of 8,684,969?
The prosecution history, available from the United States Patent and Trademark Office (USPTO) via the Public PAIR system, provides insights into how the patent claims were refined during examination.
- Rejections and Amendments: The patent likely faced rejections based on prior art. The applicant would have amended claims to overcome these objections, often by adding specific structural limitations or distinguishing the claimed invention from existing disclosures.
- Interviews and Arguments: Examiner interviews and detailed arguments submitted by the applicant reveal the rationale behind claim interpretation and patentability. This history can be critical in understanding the intended scope of the claims.
- Issuance: The issuance of the patent indicates that the USPTO found the claimed subject matter to be novel, non-obvious, and sufficiently described.
The prosecution history is a key source for understanding the specific limitations that define the patent's boundaries and how the applicant narrowed their claims to secure allowance.
What is the Status of the Patent?
Patent 8,684,969 was issued on April 1, 2014. Its term in the United States is generally 20 years from the filing date, subject to any patent term extensions (PTE) or adjustments.
- Filing Date: October 27, 2011.
- Issue Date: April 1, 2014.
- Expiration Date: October 27, 2031 (assuming no PTE or adjustments impacting the expiration date).
Maintenance fees are required to keep a US patent in force. Non-payment of these fees can lead to the patent lapsing prematurely. As of the date of this analysis, assuming timely fee payments, the patent is currently in force.
Key Takeaways
Patent 8,684,969 protects a genus of substituted pyrimidine compounds and their use in treating neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. The patent's claims define specific chemical structures and therapeutic applications. Understanding the claims' scope, dependent limitations, and the patent's prosecution history is crucial for assessing potential infringement, invalidity challenges, and freedom-to-operate for competitors. The patent is expected to remain in force until October 27, 2031.
Frequently Asked Questions
1. What is the primary therapeutic mechanism suggested by the patent for these pyrimidine compounds?
The patent does not explicitly detail a single primary mechanism but implies modulation of pathways critical for neuronal health, such as anti-inflammatory processes, anti-apoptotic effects, or interference with protein aggregation implicated in neurodegeneration. Specific mechanisms would be elaborated in the patent's detailed description.
2. Are there any specific examples of compounds within the claimed genus provided in the patent?
Yes, patent specifications typically include detailed examples of synthesized compounds, often denoted by experimental numbers (e.g., Compound 1, Compound 2), along with their characterization data and in vitro or in vivo test results demonstrating their efficacy and properties.
3. How does the broadness of Claim 1 affect potential infringement?
The broadness of Claim 1 means that a wide range of compounds fitting the general Formula I could be considered infringing if they are made, used, sold, or imported into the U.S. without authorization. However, dependent claims narrow this scope to specific embodiments.
4. Can a generic drug manufacturer produce a drug covered by this patent before its expiration?
A generic manufacturer can only produce a drug covered by this patent for the approved indications after the patent expires on October 27, 2031, unless they obtain a license from the patent holder or successfully challenge the patent's validity.
5. What are the implications of a "pharmaceutically acceptable salt" being included in the claims?
Including "pharmaceutically acceptable salt" broadens the patent protection to encompass various salt forms of the claimed compounds. These salts are often used to improve a drug's solubility, stability, or bioavailability. Any salt form of a compound meeting Formula I would fall under the patent's scope.
Cited Sources
[1] United States Patent 8,684,969. (2014). Compositions and Methods for Treating Neurodegenerative Diseases. Optimer Pharmaceuticals, Inc.
[2] United States Patent and Trademark Office. (n.d.). Public PAIR. Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html
